Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Treatment recommendations for erythrodermic psoriasis

Treatment recommendations for erythrodermic psoriasis (EP) have been published by the U.S. National Psoriasis Foundation in 2010. The evidence was based on a literature search or on evidence from expert committee reports or opinions of clinical experience of respected authorities or both. First-line treatments were ciclosporin, infliximab, acitretin and methotrexate, whereas etanercept and combination therapies were deemed second line. The combination therapies considered comprised methotrexate and infliximab, infliximab and acitretin, and ciclosporin and etretinate. The combination therapies were based on open-label, single-center studies or case reports or series (Rosenbach, M. et al. J Am Acad Dermatol 2010, 62(4): 655).